

DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR SIMULTANEOUS ESTIMATION OF PARACETAMOL, DICLOFENAC POTASSIUM AND CHLORZOXAZONE IN BULK DRUG AND TABLET DOSAGE FORM

VIJAY I. MOHITE, SACHIN E. POTAWALE, SATISH Y. GABHE*

Dept. of Pharmaceutical Chemistry, Poona College of Pharmacy, Centre for Advanced Research in Pharmaceutical Sciences (CARPS), Bharati Vidyapeeth Deemed University (BVDU), Pune 411038, India. Email: satish3619@rediffmail.com

Received: 02 Feb 2013, Revised and Accepted: 19 Mar 2013

ABSTRACT

Objective: Research study was undertaken to develop and validate simple, rapid, precise, accurate, robust High Performance Thin Layer Chromatographic (HPTLC) method for simultaneous determination of paracetamol (PARA), diclofenac potassium (DCL) and chlorzoxazone (CHL) in bulk drug and tablet dosage form.

Methods: The chromatographic separation was performed on precoated silica gel G 60 F₂₅₄ plates with toluene: ethyl acetate [55:45, v/v] as mobile phase. The detection was carried out at 271 nm.

Results: Retention factors of PARA, DCL and CHL were found to be 0.21 ± 0.01 , 0.54 ± 0.01 , and 0.74 ± 0.01 , respectively. Linearity of PARA, DCL and CHL was found to be in the concentration range of 1000-3500 ng band⁻¹, 100-350 ng band⁻¹ and 500-1750 ng band⁻¹, respectively. The % assay (Mean \pm S.D.) was found to be $100.63 \% \pm 1.2$, 103.46 ± 1.58 and $101.85 \% \pm 1.92$ for PARA, DCL and CHL, respectively. Method was validated for linearity, accuracy, precision, specificity, robustness in accordance with International Conference on Harmonisation [ICH] guidelines.

Conclusion: The proposed HPTLC method has been successfully applied for the analysis of drugs in tablet dosage formulation and applicable to routine analysis PARA, DCL and CHL in bulk drug and tablet dosage form.

Keywords: Paracetamol, Diclofenac potassium, Chlorzoxazone, Validation, High Performance Thin Layer Chromatography.

INTRODUCTION

Paracetamol, (*p*-hydroxy acetanilide) is a compound with analgesic and antipyretic activity [1, 2]. Diclofenac potassium is potassium-[(2, 6-dichlorophenyl) amino] phenylacetate. It is potassium salt of an aryl acetic acid derivative and official in USP [3-6]. It inhibits prostaglandin synthesis by interfering with the action of prostaglandin synthetase (cyclooxygenase) [7, 8]. Chlorzoxazone, (5-chloro-2(3H)-benzoxazolone), is a skeletal muscle relaxant used to decrease muscle tone and tension and thus relieve spasm and pain associated with musculoskeletal disorders [9, 10]. Literature survey revealed various analytical methods for analysis of paracetamol [11-16], diclofenac potassium [17] and chlorzoxazone [18-20], either individually or in combination with other drugs. The objective of the present research study was to develop a simple, reliable, rapid, sensitive, and accurate procedure for simultaneous densitometric analysis of paracetamol, diclofenac potassium and chlorzoxazone in combined tablet dosage form.

MATERIALS AND METHODS

Chemicals and reagents

Reference standards of paracetamol, diclofenac potassium and chlorzoxazone were gifted by Emcure Pharmaceuticals Ltd. (Pune), R.P. Drugs Ltd., (Pune, India) and Aristo Pharma Ltd. (Mumbai), respectively. Brand of tablet DICLOPOT-MR [500 mg paracetamol, 50 mg diclofenac potassium and 250 mg chlorzoxazone] was purchased from local market. All chemicals and reagents used were of analytical grade and purchased from Merck Chemicals Corporation Ltd. Mumbai, India.

Chromatographic system and conditions

HPTLC analysis were carried out on precoated silica gel aluminium plate 60F₂₅₄ (20 cm \times 10 cm with 250 μ m thickness; E. Merck, Darmstadt, Germany) in the form of bands of 6 mm width with a Hamilton syringe (100 μ L) using a Camag Linomat V (Switzerland) sample applicator. Prewashing of HPTLC plate was done with methanol followed by activation in an hot air oven at 105°C for 20 min, then cooling to room temperature. The slit dimension was kept at 5mm \times 0.45 mm and scanning speed of 10 mm/s was employed. Plate was then developed, at constant temperature, with 20 mL mobile

phase consisting of toluene: ethyl acetate (55:45, v/v). Linear ascending development was carried out in 20 cm \times 10 cm twin trough glass chamber (Camag, Muttenz, Switzerland) saturated with the mobile phase. The chamber saturation time for mobile phase was 20 min at room temperature ($25 \pm 2^\circ\text{C}$) at relative humidity of $60 \pm 5\%$. The length of chromatographic run was 8 cm. After development the plate was removed from the chamber and air-dried followed by densitometric scanning at 271 nm using a Camag TLC Scanner-3 with winCATS software version 1.4.4 in the reflectance mode.

Preparation of standard stock solutions

Preparation of Linearity Solutions

Standard stock solutions were prepared by dissolving 250 mg of paracetamol, 25 mg diclofenac potassium and 125 mg chlorzoxazone in 25 ml methanol, separately. The resulting solutions were used for further analysis.

Preparation of standard Solutions for assay

Standard stock solutions for assay were prepared by dissolving 500 mg of PARA, 50 mg DCL and 250 mg CHL in 100 ml methanol, separately. The stock solutions were further diluted with methanol to obtain a concentration of 500 μ g/ml for PARA, 50 μ g/ml for DCL and 250 μ g/ml for DCL.

Selection of detection wavelength

After chromatographic development bands were scanned over the range of 200-400 nm and the spectra were overlain. It was observed that paracetamol, diclofenac potassium and chlorzoxazone showed considerable absorbance at 271 nm and hence it was selected as the wavelength for detection (Fig1).

Method validation

The proposed HPTLC method was optimized and validated as per ICH Q2 (R1) guidelines [21].

Linearity

For preparation of calibration plots appropriate dilutions of the stock solution were prepared and applied to HPTLC plate to give a

concentration range of 1000-3500 ng spot⁻¹ for PARA, 100-350 ng spot⁻¹ for DCL, 500-1750 ng spot⁻¹ for CHL. The plate was developed as per the above mentioned method and scanned densitometrically. Each standard in six replicates was estimated

and peak areas were recorded. Peak area versus concentration was subjected to least square linear regression analysis and the intercept, slope and correlation coefficient for the calibration were determined.




Fig. 1: Overlain UV spectrum of paracetamol, diclofenac potassium and chlorzoxazone

Precision

One set of three different concentrations of mixed standard solutions of paracetamol, diclofenac potassium and chlorzoxazone were prepared. All the solutions were analyzed thrice, in order to record any intraday variations in the results. For inter day variations study, three different concentrations of mixed standard solutions in linearity range were analyzed on three consecutive days. The peak areas were recorded and relative standard deviation (RSD) was calculated.

Accuracy

Recovery studies were carried out by standard addition method in which the known amount of standard solution was added to preanalyzed sample solution at three different levels 80 %, 100 % and 120 %. These samples were then analyzed as per the procedure mentioned above and percentage recoveries estimated.

Limit of detection (LOD) and limit of quantitation (LOQ)

Limit of detection (LOD) and limit of quantitation (LOQ) were determined as $3.3 \sigma/S$ and $10 \sigma/S$, respectively. Where S is the slope of the calibration plot and σ is the standard deviation of the response (y-intercept).

Robustness studies

The effect of small, deliberate variation of the analytical conditions on the peak areas of the drugs was examined. Factors varied were

mobile phase composition (± 0.1 %) volume of mobile phase (± 0.5 %), time from application to development (+ 20 min) and from development to scanning (+ 20 min). One factor at a time was changed to study the effect. The robustness of the method was tested at 500 $\mu\text{g/ml}$ for paracetamol, 50 $\mu\text{g/ml}$ for diclofenac potassium and 250 $\mu\text{g/ml}$ for chlorzoxazone, respectively. The RSD (%) of peak area was calculated for each change of condition and was found to be within the range stipulated by ICH guidelines.

Specificity

Specificity of the method was assessed by comparing the densitograms obtained from standard drugs with those obtained from sample solutions. The developed method was found to be specific as no interference from excipients was found.

Assay of the marketed formulations

Twenty tablets were accurately weighed, their average weight was calculated and then finely powdered. A portion equivalent to about one tablet was accurately weighed and transferred to a 100 ml volumetric flask containing 50 ml methanol. It was ultrasonicated for 30 min and then diluted to 100 ml with methanol. The sample solution was then filtered using 0.45 μ filter (Millipore, Milford, MA). The stock solution was further diluted to obtain final concentration of 500 $\mu\text{g/ml}$ for paracetamol, 50 $\mu\text{g/ml}$ for diclofenac potassium and 250 $\mu\text{g/ml}$ for chlorzoxazone, respectively. Procedure was repeated six times for the analysis of marketed formulation.




Fig. 2: Representative densitogram of mixed standard solution of PAR, CHL and DCL.

RESULTS AND DISCUSSION

Different mobile phases containing various ratios of methanol, ethanol, ethyl acetate, acetone and toluene were examined. After analysis of the results the mobile phase containing toluene: ethyl acetate [55:45, v/v] was selected for analyses. The wavelength used for detection and quantitation was 271 nm. The retention factors for paracetamol, diclofenac potassium and chlorzoxazone were found to be 0.21 ± 0.01 , 0.54 ± 0.01 , and 0.74 ± 0.01 , respectively. Representative densitogram obtained from a mixed standard solution of paracetamol, diclofenac potassium and chlorzoxazone is shown in Fig 2.

The results were found to be linear over a range of 1000-3500 ng band⁻¹ for PAR, 100-350 ng band⁻¹ for CHL and 500-1750 ng band⁻¹ for DCL. The correlation coefficients (r) for the plots were 0.9987, 0.9985 and 0.9985 for PAR, CHL and DCL, respectively. Results of the

accuracy study showed satisfactory recoveries of 99.89 - 100.09 %, 99.03 - 100.28 %, 99.74 - 100.18 % for PAR, CHL and DCL, respectively indicating the reliability of the proposed HPTLC method for the quantification of these drugs in the marketed formulation (Table 1).

Robustness of the proposed HPTLC method checked after deliberate variation of the analytical parameters indicate that areas of peaks of interest and retention factor remained unaffected by small changes of the operational parameters (% RSD < 2) which demonstrated that the developed HPTLC method is robust.

The % assay (mean \pm S.D.) of marketed formulations was found to be 100.63 % \pm 1.2, 103.46 % \pm 1.58 and 101.85 % \pm 1.92 for paracetamol, diclofenac potassium and chlorzoxazone, respectively. The summary of validation parameters of proposed method are given in Table 3.

Table 1: Recovery studies of PAR, CHL and DCL.

Drug	Amount taken (ng/band)	Amount added (ng/band)	Total amount	Total Amount found (ng/band)	% Recovery	% RSD*
Paracetamol	1500	1200	2700	2697.03	99.89	0.42
	1500	1500	3000	3000.3	100.01	1.27
	1500	1800	3300	3302.97	100.09	1.16
Diclofenac Potassium	150	120	270	270.756	100.28	0.8
	150	150	300	297.57	99.19	0.72
	150	180	330	326.799	99.03	1.23
Chlorzoxazone	750	600	1350	1346.49	99.74	0.85
	750	750	1500	1502.7	100.18	1.47
	750	900	1650	1648.515	99.91	1.63

*Average of three determinations.

Table 3: Summary of validation parameters of proposed method

Parameters	Paracetamol	Diclofenac Potassium	Chlorzoxazone
Linearity range (ng / band)	1000-3500	100-350	500-1750
Correlation coefficient (r ²)	0.9987	0.9985	0.9985
LOD (ng / band)	122.92	13.50	65.81
LOQ (ng / band)	372.5	40.92	199.44
Accuracy (% Recovery)	99.99 \pm 0.95	99.94 \pm 1.31	99.5 \pm 0.916
Precision (% RSD)			
Intraday (n = 6)	1.133	1.343	1.15
Interday (n = 6)	1.153	1.436	1.136
Specificity	Specific	Specific	Specific
Robustness	Robust	Robust	Robust

CONCLUSION

The validated HPTLC method employed here proved to be simple, fast, robust, precise, accurate and thus can be used for routine analysis of paracetamol, diclofenac potassium, and chlorzoxazone in combined tablet dosage form.

ACKNOWLEDGEMENTS

The authors are thankful to Emcure Pharmaceuticals Ltd.(Pune), R.P. Drugs Ltd.(Pune, India) and Aristo Pharma. Ltd. for providing gift samples of paracetamol, diclofenac potassium and chlorzoxazone, respectively.

REFERENCES

- Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. Vol. I, Singapore: Macmillan Publishing Company; 1992. p. 656-657.
- Bailey LC, Remington: The Science and Practice of Pharmacy. 19th ed. Vol. II, Pennsylvania: Mack Publishing Company; 1995. p.1208.
- Indian Pharmacopoeia, Government of India, Ministry of Health and Family Welfare;1996,1. p. 242.
- The United State Pharmacopoeia: National Formulary-24. Asia ed. Rockville MD; 2000. p. 546.
- Budavari S, The Merck index - An encyclopedia of chemical, drugs, and biologicals.12th ed. Merck Research Laboratories, NJ: Whitehouse Station; 1996. p. 521.
- Reynolds JEF, Martindale: The Extra Pharmacopoeia. 31st Ed. London: The Royal Pharmacopoeial Society; 1996. p. 327.
- Tripathi KD, Essentials of Medical Pharmacology. 3rd ed. India: Jaypee Brothers Medical Publishers Pvt Ltd; 1995. p. 421.
- Ronald FB, Foye WO, Thomas LL and David AW, Principles of Medicinal Chemistry. 4th ed. USA: Lippincott Williams & Wilkins, B. I., Waverly Pvt. Ltd; 1996. p. 558.
- Budavari S, The Merck index - An encyclopedia of chemical, drugs, and biologicals.13th ed. Merck Research Laboratories, NJ: Whitehouse Station; 2001. p. 379-380.
- Bailey LC, Remington: The Science and Practice of Pharmacy. 19th ed. Vol. II, Pennsylvania: Mack Publishing Company; 1995. p.1033.
- Sethi PD, Charegaonkar D, Identification of drugs in Pharmaceutical formulations by HPTLC. 2 nd ed. Rep. New Delhi: CBS Publishers; 2010. p.118.
- Gandimathi M, Ravi TK, Shukla N, Sowmiya G High performance thin layer chromatographic method for simultaneous

- estimation of paracetamol and valdecoxib in tablet dosage form. *Indian J Pharm Sci* 2007; 69(1):145.
13. Chawla JL, Sodhi RA, Sane RT Simultaneous determination of chlorzoxazone, paracetamol and diclofenac sodium by different chromatographic techniques. *Indian Drugs* 1996; 33(4): 171-178.
 14. Kachrimanis K, Braun DE, Griesser UJ Quantitative analysis of paracetamol polymorphs in powder mixtures by FT-Raman spectroscopy and PLS regression. *J Pharm Biomed Anal* 2007; 43: 407-412.
 15. Deshpande PB, Gandhi SV, Bhangale YS, Pisal VB High Performance Thin Layer Chromatographic Analysis of Paracetamol and Etodolac in Spiked Human Plasma. *J Pharm Biomed Sci* 2010; 7(13): 1-5.
 16. Puranik M, Hirudkar A, Wadher SJ, Yeole PG Development and validation of spectrophotometric methods for simultaneous estimation of tramadol hydrochloride and chlorzoxazone in tablet dosage form. *Indian J Pharm Sci* 2006; 68(6): 737-739.
 17. Potawale SE, Nanda RK, Bhagwat VV, Hamane SC, Deshmukh RS, Puttamsetti K Development and validation of a HPTLC method for simultaneous densitometric analysis of Diclofenac potassium and Dicyclomine hydrochloride as the bulk drugs and in the tablet dosage form. *J Pharm Res* 2011; 4(9): 3116-3118.
 18. Garg G, Saraf SS, Saraf S Simultaneous estimation of aceclofenac, paracetamol and chlorzoxazone in tablets. *Indian J Pharm Sci* 2007; 69 (5): 692-694.
 19. Mahajan VK, Bari SB, Shirkhedkar AA, Surana SJ Simultaneous densitometric TLC analysis of aceclofenac, paracetamol, and chlorzoxazone in tablets. *Acta Chromatogr* 2008; 20(4):625-636.
 20. Yuvaraj G, PavanKumar P, Elangovan N The Simultaneous Estimation of Aceclofenac, Paracetamol and Chlorzoxazone in Pharmaceutical Dosage Forms by HPTLC. *International J Chem Pharm Sci* 2010; 1 (2):25-27.
 21. International Conference on Harmonization (2005) ICH harmonised tripartite guideline Validation of analytical procedures: text and methodology Q2 (R1) ICH, Geneva, Nov (2005).